Clinical Obsevation of Gefitinib on Mutational Unknown Non-small Cell Lung Cancer in End Stage_West China Medical Journal

Authors：

LIU Dingyi ,  ZHU Li , ZHANG Jiliang , LIU Hong

Medical Oncology, Chengdu Tumor Hospital, Chengdu, Sichuan 610021, P.R.China;

Corresponding author：

ZHU Li, Email: liudingyi7979@126.com

Keywords：

肺癌; 吉非替尼; 突变未知; 生活质量

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

【摘要】目的 评估吉非替尼治疗终末期（PS评分≥3分）非小细胞肺癌（NSCLC）的临床效果和生活质量改善情况。方法 2008年5月-2010年6月共收治终末期NSCLC患者40例，其中19例患者采用吉非替尼治疗（治疗组），21例采用支持治疗+中药治疗（对照组）。结果治疗6个月后，治疗组19例患者中，CR 1例，PR 5例，SD 10例，PD 3例。治疗组有效率为31.5%（6/19），临床受益率为84.2%（16/19）。对照组21例中，SD 5例，PD 16例，无CR。对照组有效率为23.8%（5/21），临床受益率为 23.8%（5/21）。两组间有效率和临床受益率比较，差异均有统计学意义（P lt;0.05）。治疗组中位生存期为13.2个月，对照组中位生存期为4.5个月。结论吉非替尼可延长NSCLC患者的生存期，改善其生活质量。
【Abstract】 Objective To evaluate the curative effect and life improvement of gefitinib on non-small cell lung cancer (NSCLC) which in the end stage. Methods Forty patients with end-stage NSCLC were treated from May 2008 to June 2010. Nineteen patients of them were treated with gefitinib (treatment group), 21 patients were treated with supportive care and traditional Chinese medicine treatment (control group). Results Six months after treatment, there are one patient with CR, five patients with PR, 10 patients with SD and three patients with PD in the treatment group. The effective rate of treatment group was 31.5% (6/19), clinical benefit rate was 84.2% (16/19). There are five patients with SD, 16 patients with PD, and no one with CR in the control group. The effective rate of the control group was 23.8% (5/21), clinical benefit rate was 23.8% (5/21). The differences of effective rate and clinical benefit rate between two groups were statistically significant (P lt;0.05). The median survival period of the treatment group and control group were 13.2 and 4.5 months respectively. Conclusion Gefitinib can extend the lifetime of NSCLC patients and improve their quality of life.

Citation： LIU Dingyi,ZHU Li,ZHANG Jiliang,LIU Hong. Clinical Obsevation of Gefitinib on Mutational Unknown Non-small Cell Lung Cancer in End Stage. West China Medical Journal, 2010, 25(8): 1423-1425. doi: Copy

1.	孙燕, 石远凯. 临床肿瘤内科手册[M]. 北京: 人民卫生出版社, 2008: 388-424.
2.	韩宝惠. 从靶向治疗看非小细胞肺癌患者的生活质量[J]. 中国肺癌杂志, 2009, 6(6): 615-616.
3.	Saijo N, Takeuchi M, Kunitoh H. Reasons for response differences seen in the V 15-32 INTEREST and IPASS trials[J]. Nat Rey Clin Onco, 2009, 6(5): 287-294.
4.	Sanford M, Scott LJ. Gefitinib a review of its use in the treatm ent of locally advanced/m etastatic non-small cell lung cancer[J]. Drugs, 2009, 69(16): 2303-2328.
5.	Ebi N, Semba H, Tokunaga SJ, et al. A phase Ⅱ trial of gefitinib monotherapy in chem. Otherapy-nave patients of 75 years or olderw ith advanced non-small cell lung cancer[J]. J Thorac Onco, 2008, 3(10): 1166-1171.
6.	鲍云华, 李俭杰. 介绍新的实体瘤治疗反应评价标准(RECIST) [J]. 中国肺癌杂志, 2005, 8(1): 77-78.
7.	周清华, 王瑾, 许峰, 等. 2005年美国国家综合癌症网(NCCN)非小细胞肺癌临床指南[J]. 中国肺癌杂志, 2005, 8(4): 332-346.
8.	Inoue A, Kobayashi. First-line gefitin ib for patients withadvanced non-snall lung cancer harboring eprdemal grow th factor receptor mutations without indication for chemotherapy[J]. J ClimOncoj, 2009, 27(9): 1350-1354.
9.	Fischer JR, GeigerD. Successful individualized and targeted therapy of an NSCLC patient with Gefitinib based on a predictive assessm ent of the EGF-receptormutation status [J]. Pneumologie, 2007, 61(4): 264-269.
10.	Yoshida K, Yatabe Y, Park JY, et al. Prospective validation for prediction of gefitinib sensitivity by epidemalgrow th factor receptor gene mutation in patients with non-small cell lung cancer[J]. J Thorac Oncol, 2007, 2(1): 22-28.
11.	Varella-Garcia M, Mitsudami T, Yatabe Y, et al. EGFR and HER2 genam ic gain in recurrent non-small cell lung cancer after sungery im pact on outcame to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort [J]. J Thorac Onco, 2009, 4(3): 318-325.
12.	杨衿记, 吴一龙. 先睹为快[J]. 循证医学, 2009, 8(4): 66.
13.	Wu YL, Zhong WZ, Li LY, et al. Epiderm al grow th factor receptor mutations and their correlation with grfitinib therapy in patients with non-small cell lung cancer ameta-analysis based on updated individual patient data from six medical centers in mainland China[J]. J Thorac Oncol, 2007, 2(5): 430-439.

1. 孙燕, 石远凯. 临床肿瘤内科手册[M]. 北京: 人民卫生出版社, 2008: 388-424.
2. 韩宝惠. 从靶向治疗看非小细胞肺癌患者的生活质量[J]. 中国肺癌杂志, 2009, 6(6): 615-616.
3. Saijo N, Takeuchi M, Kunitoh H. Reasons for response differences seen in the V 15-32 INTEREST and IPASS trials[J]. Nat Rey Clin Onco, 2009, 6(5): 287-294.
4. Sanford M, Scott LJ. Gefitinib a review of its use in the treatm ent of locally advanced/m etastatic non-small cell lung cancer[J]. Drugs, 2009, 69(16): 2303-2328.
5. Ebi N, Semba H, Tokunaga SJ, et al. A phase Ⅱ trial of gefitinib monotherapy in chem. Otherapy-nave patients of 75 years or olderw ith advanced non-small cell lung cancer[J]. J Thorac Onco, 2008, 3(10): 1166-1171.
6. 鲍云华, 李俭杰. 介绍新的实体瘤治疗反应评价标准(RECIST) [J]. 中国肺癌杂志, 2005, 8(1): 77-78.
7. 周清华, 王瑾, 许峰, 等. 2005年美国国家综合癌症网(NCCN)非小细胞肺癌临床指南[J]. 中国肺癌杂志, 2005, 8(4): 332-346.
8. Inoue A, Kobayashi. First-line gefitin ib for patients withadvanced non-snall lung cancer harboring eprdemal grow th factor receptor mutations without indication for chemotherapy[J]. J ClimOncoj, 2009, 27(9): 1350-1354.
9. Fischer JR, GeigerD. Successful individualized and targeted therapy of an NSCLC patient with Gefitinib based on a predictive assessm ent of the EGF-receptormutation status [J]. Pneumologie, 2007, 61(4): 264-269.
10. Yoshida K, Yatabe Y, Park JY, et al. Prospective validation for prediction of gefitinib sensitivity by epidemalgrow th factor receptor gene mutation in patients with non-small cell lung cancer[J]. J Thorac Oncol, 2007, 2(1): 22-28.
11. Varella-Garcia M, Mitsudami T, Yatabe Y, et al. EGFR and HER2 genam ic gain in recurrent non-small cell lung cancer after sungery im pact on outcame to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort [J]. J Thorac Onco, 2009, 4(3): 318-325.
12. 杨衿记, 吴一龙. 先睹为快[J]. 循证医学, 2009, 8(4): 66.
13. Wu YL, Zhong WZ, Li LY, et al. Epiderm al grow th factor receptor mutations and their correlation with grfitinib therapy in patients with non-small cell lung cancer ameta-analysis based on updated individual patient data from six medical centers in mainland China[J]. J Thorac Oncol, 2007, 2(5): 430-439.

West China Medical Journal

Clinical Obsevation of Gefitinib on Mutational Unknown Non-small Cell Lung Cancer in End Stage

Abstract Full text Figures/Tables Video References Cited by

Format

Content